CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 110,662	$ 142,090
Restricted cash	1,738	0
Research and development incentives receivable	7,139	4,908
Prepaid expenses and other current assets	6,203	9,907
Total current assets	125,742	156,905
Goodwill	0	12,209
Property and equipment, net	7,373	11,821
Intangible assets, net	21,947	25,108
Right of use assets, net	4,384	7,581
Other assets	881	882
Total assets	160,327	214,506
Current liabilities:
Accounts payable	2,474	1,601
Accrued expenses and other current liabilities	9,525	9,212
Deferred income	1,738	0
Operating lease liability - current	1,920	1,785
Total current liabilities	15,657	12,598
Non-current liabilities:
Operating lease liability - non-current	10,087	11,191
Contingent consideration	2,650	1,823
Other non-current liabilities	1,360	1,325
Deferred tax liability, net	438	574
Total liabilities	30,192	27,511
Commitments and contingencies (Note 17)
Stockholders’ equity:
Ordinary shares, £0.000025 nominal value; 40,234,663 shares authorized, issued and outstanding (December 31, 2023: authorized, issued and outstanding: 38,643,540)	1	1
Additional paid-in capital	393,474	386,602
Accumulated deficit	(237,664)	(176,590)
Accumulated other comprehensive loss – foreign currency translation adjustments	(25,868)	(23,315)
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders	130,029	186,784
Noncontrolling interest	106	211
Total stockholders’ equity	130,135	186,995
Total liabilities and stockholders’ equity	160,327	214,506
Deferred A shares
Stockholders’ equity:
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2023: authorized, issued and outstanding: 63,443)	$ 86	$ 86